About the test

The Oncotype DX assay is a 21-gene assay that predicts the likelihood of chemotherapy benefit and 10-year risk of distant recurrence to inform adjuvant treatment decisions in certain women with early-stage invasive breast cancer.

The Oncotype DX Assay:

• Supports your treatment decisions - The Oncotype DX assay is incorporated in the ASCO^®, NCCN^®, St. Gallen and ESMO^® guidelines, and is recommended by NICE for use in clinical practice to guide adjuvant chemotherapy treatment decisions for certain patients with early-stage breast cancer, including micrometastatic disease. Access this guidance.
• Informs treatment decisions and improves confidence in treatment decisions for physicians and patients. Studies suggest that the results of the assay change breast cancer treatment decisions in approximately 30% of cases.^1-8
• Offers expanded clinical utility-Enhanced reports now include quantitative ER, PR and HER2 values.

Extensively Validated and Ordered

• The clinical value of the Oncotype DX assay was shown in clinical studies involving nearly 4,000 patients
• Over 900,000 patients worldwide have received the information provided by the Oncotype DX assay
• Over 19,000 physicians have ordered the Oncotype DX assay in over 90 countries
• Genomic Health is a CLIA-certified, CAP-accredited reference laboratory and is a leader in the field of cancer genomics